Get the Stockscreener App
0.6755
4.89%
-0.0605
Aptorum Group Ltd stock is traded at $0.6755, with a volume of 6,989.
It is down -4.89% in the last 24 hours and down -58.82% over the past month.
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
See More
Previous Close:
$0.736
Open:
$0.6845
24h Volume:
6,989
Relative Volume:
0.23
Market Cap:
$3.70M
Revenue:
$1.20M
Net Income/Loss:
$-2.82M
P/E Ratio:
-0.2487
EPS:
-2.7164
Net Cash Flow:
$-7.73M
1W Performance:
-36.36%
1M Performance:
-58.82%
6M Performance:
-81.82%
1Y Performance:
-56.66%
1-Day Range:
$0.6755
$0.6845
1-Week Range:
$0.46
$1.04
52-Week Range:
$0.46
$17.49
Aptorum Group Ltd Stock (APM) Company Profile
Compare APM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| APM | 0.6755 | 3.70M | 1.20M | -2.82M | -7.73M | -2.7164 |
| VRTX | 445.50 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 737.53 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 585.04 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.28 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.21 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Aptorum Group Ltd Stock (APM) Latest News
Aptorum Group Stock Hits 52-Week Low at $1.2 Amid Market Challenges - Investing.com Canada
Aptorum Group announces annual shareholder meeting details By Investing.com - Investing.com Australia
Aptorum Group announces annual shareholder meeting details - Investing.com India
Aptorum stock hits 52-week low at $1.34 amid market challenges - Investing.com India
Oil prices soar after OPEC+ delays production hike - Investing.com
Andean Precious Metals (CVE:APM) Upgraded at Desjardins - Defense World
Aptorum Group stock hits 52-week low at $1.35 amid market challenges - Investing.com Australia
Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10 - AsiaOne
Andean Precious Metals (CVE:APM) Reaches New 1-Year High Following Insider Buying Activity - MarketBeat
Oncology And Infectious Diseases Focused Aptorum Stock Skyrockets 7X On WednesdayHere's Why - MSN
Aptorum Group Limited (NASDAQ:APM) Sees Large Growth in Short Interest - Defense World
Aptorum Group Limited (NASDAQ:APM) Short Interest Down 47.1% in July - Defense World
Aptorum Group Limited (NASDAQ:APM) Short Interest Update - Defense World
NASDAQ – Stock Price, Charts & News Today - BNN Bloomberg
Aptorum Group (NASDAQ:APM) Trading Up 0.4% - Defense World
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update30.04.2024 - wallstreet:online
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Markets Insider
symbol__ Stock Quote Price and Forecast - CNN
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Markets Insider
Nasdaq Rises 100 Points; BJ's Wholesale Posts Weak Sales - Benzinga
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a ... - sharewise
Aptorum and YOOV announce merger plan - Investing.com
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023 - Business Wire
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets - Yahoo Finance
Aptorum Group Limited Announces Resignation of Thomas Lee as Head of Research and Development - Marketscreener.com
Why Is Aptorum (APM) Stock Down 16% Today? - InvestorPlace
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group - Business Wire
Menopause Market Size, Share And Trends Report, 2031 - SkyQuest Technology
Cotações de Ações Americanas (STOCKS) - Money Times
DelveInsight Estimates a Promising Picture of Obesity Pipeline Space Landscape as Key 100+ Pharma Companies Working in the Space - PR Newswire
Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics - ACROFAN
Notice to Boustead Securities Customers Who Purchased IPOs - GlobeNewswire
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021 - Business Wire
Aptorum GroupAPMHigh RIsk Biotech Stocks Buy, Sell, Hold Investing Analysis for the Long-run - The Market Oracle
NY-APTORUM-GROUP-LIMITED | Business Wire - Via Ritzau
Aptorum Gr (NASDAQ:APM) Stock Quotes, Forecast and News Summary - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
42 Stocks Moving in Thursday's Pre-Market SessionC3.ai (NYSE:AI) - Benzinga
40 Stocks Moving in Monday's Pre-Market SessionAMC Enter Hldgs (NYSE:AMC), Aptorum Gr (NASDAQ:APM) - Benzinga
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020 - businesswire.com
Aptorum Group Limited (NASDAQ:APM) Unveils Infectious Disease Liquid Biopsy Subsidiary to Co-develop RPIDD Tech - BP Journal
45 Stocks Moving in Wednesday's Pre-Market SessionAdial Pharmaceuticals (NASDAQ:ADIL), Aptorum Gr (NAS - Benzinga
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Geno - AsiaOne
Aptorum Group Ltd (NASDAQ:APM) Pleased To Unveil Video Indicating Positive Results On SACT-1 - BP Journal
Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models - Business Wire
Sharp thinking in medicine | The Standard - Hong Kong Standard
Yam for maam: Aptorum Group to launch women’s bone health supplement made from Chinese yam - NutraIngredients-Asia
Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020 - AsiaOne
Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co-Working Laboratory Ecosystems for Life Sciences Start-Ups in the United States - BioSpace
Argus Research Initiates Equity Research Report Coverage on Aptorum Group Limited (NasdaqGM: APM) - GlobeNewswire
Hong Kong pharma start-up joins Singapore technology agency in venture fund - South China Morning Post
Aptorum Group Ltd Stock (APM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):